CD4 and neoplasm: Taken together, our findings that L-fuc leverages anti-tumor immunity through both CD4+ T cells (68), and now potentially DCs, suggest that the treatment of cancer with oral L-fuc can bolster a patient’s anti-tumor immune responses and provide preclinical rationale to combine L-fuc with DC-mediated immunotherapeutic approaches.